Mesoblast chief executive Silviu Itescu called the results of the treatment "a remarkable clinical outcome in these critically ill patients". © 2020 Forbes Media LLC. Even so, Mesoblast's … It even kills younger patients and people who have no other underlying conditions.
According to the CDC, between 20-42% of hospitalized COVID-19 patients develop ARDS, with as many as 85% of patients admitted to intensive care having this complication. Mesoblast said in a recent clinical study which tested MSCs in seven patients with severe Covid-19 pneumonia, the treatment either completely cured or significantly improved functional outcomes for all patients.
Doctors involved with that project said at the time that vaccines will be the miracle drug everyone is waiting for, not stem cell therapy. Itescu's genius was to find possible applications of Remestemcel-L from a review of a relatively small but significant study conducted in China earlier this year into COVID-19 patients. The treatment involves intravenously injecting stem cells, which are believed to limit the inflammation in a patient's lungs. Cann Global (CGB) is set to launch uniquely-formulated medicinal cannabis products under the Canntab range into Australia for the first time.
They’re drugs that work and can save lives, but they won’t save everyone. One of the diseases the company has been working to treat is graft-vs-host disease, a condition that arises in patients who receive bone marrow transplants. Up to 80% of affected children can die if steroids don’t stop the inflammation. For reference, the total mortality rate for Covid-19 is roughly 3.5 per cent. The purpose of the randomized, controlled clinical trial is to test that survival rate on a larger scale. A man lies in a hospital bed sick with COVID-19, the dangerous disease caused by the novel coronavirus. Mesoblast also noted that post-hoc analysis of a 60-patient chronic obstructive pulmonary disease study showed Remestemcel-L infusions were “well tolerated”. Even so, Mesoblast's shares jumped 22 per cent to $2.40 by mid-morning, up from a low of $1.10 in March but well below their year high of $3.07 in January. Mesoblast told shareholders today it will be testing its remestemcel-L product on coronavirus patients who develop acute respiratory distress syndrome (ARDS) from the infection. It’s caused by what’s known as a “cytokine storm” - an overreaction of the immune system in which the body ends up damaging the lungs in an attempt to destroy the coronavirus and the lung cells that it has infected. Mesoblast (ASX: MSB) is the latest ASX company to potentially benefit commercially from the coronavirus global epidemic after revealing it would be evaluating its anti-inflammatory product in COVID-19 patients that have developed acute respiratory distress. Mesoblast's stem cells replicating during the manufacturing process. There may be a conflict of interest present with commercial arrangements with companies and/or stock held.
ARDS occurs due to an excessive immune response against the COVID-19 virus in the lungs, with the inflammatory cytokines produced by the immune cells – dubbed a "cytokine storm" – destroying the lung tissue. However, Mesoblast anticipates its Remestemcel-L product could potentially have clinical benefit to COVID-19 sufferers that have progressed to respiratory distress. Researchers found that MSCs can increase the number of T cells and reduce inflammation at the same time.
For coronavirus patients, ARDS is one of the deadliest complications of the disease, and often ends up requiring the use of ventilators in order to ensure they’re getting sufficient oxygen. But it turns out there may be a drug that does qualify as a “miracle COVID-19 cure,” one that might save plenty of severe COVID-19 patients. According to Mesoblast, patients with COVID-19 that have developed acute respiratory distress syndrome have an almost 50% fatality rate. To implement the evaluation of its proprietary Remestemcel-L anti-inflammatory allogenic mesenchymal stem cell product, Mesoblast is in active discussions with government and regulatory authorities, medical institutions and pharmaceutical companies across Australia, the US, China and Europe. Mesoblast's Silviu Itescu could soon be seeing the benefits of years of research in COVID-19 patients. Using Mesoblast’s treatment for coronavirus patients with ARDS “has a rationale behind it” says Dr. Wayne Marasco, who’s studied a number of coronavirus diseases and is currently researching potential antibody treatments for COVID-19. Mesoblast is focused on creating a treatment for the worst-affected COVID-19 patients. Biotech stock reversed course last week, dragged lower by the broader market weakness. World Muscle Society, or WMS, 25: Virtual Congress: Sept. … To implement the evaluation of its proprietary Remestemcel-L anti-inflammatory allogenic mesenchymal stem cell product, Mesoblast is … As the world scrambles to nullify the impact of the spreading Covid-19 coronavirus, ASX-listed biotech Mesoblast (MSB) has thrown its hat in the ring.
David Rowe. Chris Smith started writing about gadgets as a hobby, and before he knew it he was sharing his views on tech stuff with readers around the world. Cleveland-based Athersys, which is working on stem cell therapies for strokes, heart disease and other conditions, is also expected to. The FDA was quick to allow Mesoblast to start an investigational study of COVID-19 patients in the US because it was already being used in a number of clinical trials in the US across several inflammatory conditions, including in elderly patients with lung disease and adults and children with steroid-refractory acute graft versus host disease (aGVHD).
The report mentions two pilot studies, one from Mount Sinai Hosptial in March and one published in The Lancet in July. Moreover, Covid-19 patients who developed severe ARDS were more likely to be elderly and have co-existing conditions like diabetes and chronic kidney disease. The novel coronavirus is an incredibly scary illness given the complex way it operates.
“We were very pleased with preliminary data demonstrating the cells seem to have benefitted some of these patients,” says CEO Silviu Itescu. Our daily reporting, in your inbox. The randomized, double-blinded, controlled trial will evaluate Mesoblast's mesenchymal stem cell product, remestemcel-L, plus maximal care in ARDS, the main cause of death in patients with COVID-19. The good news is that doctors and researchers have not run out of ideas in their quest to beat the novel virus.
Among those ICU patients who develop ARDS, over 40% die (some studies show that number as high as 72%) and those who survive spend an average of 10-13 days in the hospital.
Years of work in stem cell therapy technology by Mesoblast could soon be used to help COVID-19 patients in the United States facing the final and worst phase of the virus. Cleveland-based Athersys, which is working on stem cell therapies for strokes, heart disease and other conditions, is also expected to begin clinical trials soon. All rights reserved. Stem cell specialist Mesoblast (MSB) is joining the race to treat Covid-19 coronavirus patients The company will test its remestemcel-L product on Covid-19 patients who develop acute respiratory distress syndrome (ARDS) According to Mesoblast, this condition is the principal cause of death in Covid-19 Now, the drug will be tested on coronavirus patients in the U.S., Australia, China, and Europe. At time of writing, total confirmed cases were approaching 114,000, while total deaths were just under 4000. The worst phase of COVID-19 occurs when the patient suffers a cytokine storm, which is an overproduction of immune cells and their activating compounds (cytokines). Years of work in stem cell therapy technology by Mesoblast could soon be used to help COVID-19 … These cytokines also damage other organs such as liver, kidney and heart. Injured tissues normalized,” Kimberlin wrote.